---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-093220"
form_type: "8-K"
ticker: "RMTG"
cik: "0001760026"
company_name: "Regenerative Medical Technology Group Inc."
filed_at: "2026-08-25T10:06:43+00:00"
generated_at: "2026-08-25T10:10:22.556784+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# RMTG Q1 revenue up 90% YoY, Q2 quadrupled; Argentina license, Cancun lab expansion

## Summary
- Q1 2026 revenue up 90% YoY; Q2 revenue quadrupled YoY; 2025 total revenue $5.1M.
- Argentina granted first-ever license to harvest/produce biologics; Cancun lab added 2 clean rooms with COFEPRIS sign-off.
- ISSCA AI launched with 30 years of 60M redacted patient records to power physician tool.
- BKFC partnership continues; fighter Ben Rothwell treated; more announcements expected.
- Company evaluating capital raising strategies; may increase authorized shares; Nasdaq uplisting desired but no timeline.

## SEC filing metadata
- accession: 0001213900-26-093220
- form_type: 8-K
- ticker: RMTG
- cik: 0001760026
- company_name: Regenerative Medical Technology Group Inc.
- filed_at: 2026-08-25T10:06:43+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760026/000121390026093220/0001213900-26-093220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760026/000121390026093220/ea0303255-8k_regenerative.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-093220
- JSON: https://secwatch.observer/filing/0001213900-26-093220.json
- Plain text: https://secwatch.observer/filing/0001213900-26-093220.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.